SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-141699
Filing Date
2024-05-17
Accepted
2024-05-17 16:01:57
Documents
14
Period of Report
2024-05-15
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d816353d8k.htm   iXBRL 8-K 38935
2 EX-3.1 d816353dex31.htm EX-3.1 28676
  Complete submission text file 0001193125-24-141699.txt   201843

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20240515.xsd EX-101.SCH 2836
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20240515_lab.xml EX-101.LAB 18740
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20240515_pre.xml EX-101.PRE 11698
17 EXTRACTED XBRL INSTANCE DOCUMENT d816353d8k_htm.xml XML 3860
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 24959447
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)